8-K Announcements
6Material company update
Mar 26, 2026·SEC
Material company update
Mar 5, 2026·SEC
Material company update
Jan 7, 2026·SEC
BridgeBio Oncology Therapeutics Inc.(BBOT)Earnings, Financials & Key Ratios
BBOT•NASDAQ
$7.86
$185M mkt cap·Price updated May 7, 2026
AboutBridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways. The company recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development. The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.Show more
- Revenue$0
- EBITDA-$146M-80.8%
- Net Income-$134M-80.5%
- EPS (Diluted)-4.30-1034.8%
- ROE-44.7%+43.2%
- ROIC-96.27%-48.4%
- Debt/Equity0.01
BBOT Key Insights
BridgeBio Oncology Therapeutics Inc. (BBOT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.6x book value
✗Weaknesses
- ✗Shares diluted 87.2% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
BBOT Price & Volume
BridgeBio Oncology Therapeutics Inc. (BBOT) stock price & volume — 10-year historical chart
Loading chart...
BBOT Growth Metrics
BridgeBio Oncology Therapeutics Inc. (BBOT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-80.47%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-803.89%
Return on Capital
10 Years-87548.75%
5 Years-87548.75%
3 Years-116727.24%
Last Year-48%
BBOT Recent Earnings
BridgeBio Oncology Therapeutics Inc. (BBOT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 1/11 qtrs (33%)
Q2 2026Latest
Mar 5, 2026EPS
$0.49
Est $0.63
+22.6%
Revenue
—
Q2 2026
Mar 4, 2026EPS
$0.56
Est $0.42
-33.3%
Revenue
—
Q4 2025
Nov 12, 2025EPS
$1.03
Est $0.41
-151.2%
Revenue
—
Q3 2025
Aug 1, 2025EPS
$0.04
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 5, 2026 | $0.49vs $0.63+22.6% | — |
| Q2 2026 | Mar 4, 2026 | $0.56vs $0.42-33.3% | — |
| Q4 2025 | Nov 12, 2025 | $1.03vs $0.41-151.2% | — |
| Q3 2025 | Aug 1, 2025 | $0.04 | — |
Based on last 11 quarters of dataView full earnings history →
BBOT Peer Comparison
BridgeBio Oncology Therapeutics Inc. (BBOT) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BBIO | 13.08B | 67.45 | -17.80 | 126.26% | -128.25% | |||
 KYMR | 6.91B | 84.63 | -22.94 | -16.72% | -6.12% | -25.02% | 0.05 | |
 TPVG | 242.54M | 5.99 | 4.91 | 36.55% | -3.39% | 1.33 | ||
 RVMD | 30.3B | 142.51 | -23.95 | -83.22% | 0.10 | |||
 KRYS | 8.75B | 296.70 | 43.38 | 33.94% | 53.92% | 19.25% | 0.01 | |
 AUPH | 2B | 15.14 | 7.31 | 20.38% | 101.47% | 49.4% | 0.13 | |
 MGNX | 186.16M | 2.94 | -2.49 | 0.78% | -49.91% | -120.2% | 0.66 | |
 IMVT | 5.53B | 27.22 | -9.97 | -47.07% | 0.00 |
Compare BBOT vs Peers
BridgeBio Oncology Therapeutics Inc. (BBOT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BBOT Income Statement
BridgeBio Oncology Therapeutics Inc. (BBOT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
| Gross Margin % | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - |
| Operating Expenses | 43.36K | 3.52K | 64.77M | 80.86M | 145.82M |
| OpEx % of Revenue | - | - | - | - | - |
| Selling, General & Admin | 43.36K | 3.52K | 8.48M | 7.76M | 24.62M |
| SG&A % of Revenue | - | - | - | - | - |
| Research & Development | 0 | 0 | 56.29M | 73.11M | 121.2M |
| R&D % of Revenue | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -43.36K▲ 0% | -3.52K▲ 91.9% | -64.77M▼ 1839985.2% | -80.86M▼ 24.8% | -145.82M▼ 80.3% |
| Operating Margin % | - | - | - | - | - |
| Operating Income Growth % | - | 91.88% | -1839985.23% | -24.84% | -80.33% |
| EBITDA | -43.36K | -3.52K | -64.68M | -80.66M | -145.82M |
| EBITDA Margin % | - | - | - | - | - |
| EBITDA Growth % | - | 91.88% | -1837371.59% | -24.7% | -80.79% |
| D&A (Non-Cash Add-back) | 0 | 0 | 92K | 208K | 0 |
| EBIT | -43.36K | -3.52K | -64.77M | -80.86M | 0 |
| Net Interest Income | 0 | 0 | 72K | 8.46M | 0 |
| Interest Income | 0 | 0 | 72K | 8.46M | 11.34M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 0 | 0 | 72K | 8.18M | 11.78M |
| Pretax Income | -43.36K▲ 0% | -3.52K▲ 91.9% | -64.7M▼ 1837939.8% | -74.28M▼ 14.8% | -134.04M▼ 80.5% |
| Pretax Margin % | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% |
| Net Income | -43.36K▲ 0% | -3.52K▲ 91.9% | -64.7M▼ 1837939.8% | -74.28M▼ 14.8% | -134.04M▼ 80.5% |
| Net Margin % | - | - | - | - | - |
| Net Income Growth % | - | 91.88% | -1837939.77% | -14.8% | -80.47% |
| Net Income (Continuing) | -43.36K | -3.52K | -64.7M | 7.6M | -134.04M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.00▲ 0% | -0.00▲ 57.1% | -0.00▼ 122.2% | 0.46▲ 23100.0% | -4.30▼ 1034.8% |
| EPS Growth % | - | - | - | - | -1034.78% |
| EPS (Basic) | -0.00 | 0.00 | -0.00 | 0.46 | -4.30 |
| Diluted Shares Outstanding | 20.48M | 20.48M | 20.48M | 16.64M | 31.14M |
| Basic Shares Outstanding | 20.48M | 20.48M | 20.48M | 16.64M | 31.14M |
| Dividend Payout Ratio | - | - | - | - | - |
BBOT Balance Sheet
BridgeBio Oncology Therapeutics Inc. (BBOT) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|
| Total Current Assets | 0 | 0 | 0 | 1.95M | 425.46M |
| Cash & Short-Term Investments | 0 | 0 | 0 | 1.7M | 425.46M |
| Cash Only | 0 | 0 | 0 | 1.7M | 373.69M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 425.46M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 144.28K | 144.58K | 332.89K | 192.47M | 22.92M |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 192.45M | 0 |
| Other Non-Current Assets | 144.28K | 144.58K | 332.89K | 25.13K | 22.92M |
| Total Assets | 144.28K▲ 0% | 144.58K▲ 0.2% | 332.89K▲ 130.3% | 194.42M▲ 58304.2% | 448.38M▲ 130.6% |
| Asset Turnover | - | - | - | - | - |
| Asset Growth % | - | 0.21% | 130.25% | 58304.24% | 130.62% |
| Total Current Liabilities | 162.64K | 166.46K | 396.46K | 187.51K | 35.04M |
| Accounts Payable | 0 | 0 | 0 | 0 | 0 |
| Days Payables Outstanding | - | - | - | - | - |
| Short-Term Debt | 36.96K | 43.11K | 70.09K | 0 | 522K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 34.52M |
| Current Ratio | - | - | - | 10.40x | 12.14x |
| Quick Ratio | - | - | - | 10.40x | 12.14x |
| Cash Conversion Cycle | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 | 5.52M | 2.24M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 2.24M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 5.52M | 0 |
| Total Liabilities | 162.64K | 166.46K | 396.46K | 5.71M | 37.28M |
| Total Debt | 36.96K | 43.11K | 70.09K | 0 | 2.77M |
| Net Debt | 36.96K | 43.11K | 70.09K | -1.7M | -370.92M |
| Debt / Equity | - | - | - | - | 0.01x |
| Debt / EBITDA | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - |
| Total Equity | -18.36K▲ 0% | -21.88K▼ 19.2% | -63.57K▼ 190.6% | 188.72M▲ 296969.0% | 411.1M▲ 117.8% |
| Equity Growth % | - | -19.18% | -190.57% | 296969.04% | 117.84% |
| Book Value per Share | -0.00 | -0.00 | -0.00 | 11.34 | 13.20 |
| Total Shareholders' Equity | -18.36K | -21.88K | -63.57K | 188.72M | 411.1M |
| Common Stock | 288 | 288 | 460 | 192.45M | 8K |
| Retained Earnings | -43.36K | -46.88K | -88.57K | -3.73M | -356.57M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 16K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
BBOT Cash Flow Statement
BridgeBio Oncology Therapeutics Inc. (BBOT) cash flow — operating, investing & free cash flow history
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|
| Cash from Operations | 0 | 0 | 0 | -763.82K | -113.89M |
| Operating CF Margin % | - | - | - | - | - |
| Operating CF Growth % | - | - | - | - | -14811.1% |
| Net Income | -74 | -3.52K | -41.69K | 7.6M | -134.04M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 610K |
| Stock-Based Compensation | 0 | 0 | 0 | 271.57K | 5.87M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 74 | 3.52K | 26.69K | -8.53M | 13.67M |
| Working Capital Changes | 0 | 0 | 15K | -104.61K | 0 |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 172.51K | -1.84M |
| Cash from Investing | 0 | 0 | 0 | -184M | 73.33M |
| Capital Expenditures | 0 | 0 | 0 | 0 | -606K |
| CapEx % of Revenue | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 0 | 0 | 0 | 186.46M | 383.4M |
| Debt Issued (Net) | 0 | 0 | 0 | -209.85K | 0 |
| Equity Issued (Net) | 0 | 0 | 0 | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | -578.55K | 383.4M |
| Net Change in Cash | 0▲ 0% | 0▲ 0% | 0▲ 0% | 1.7M▲ 0% | 342.84M▲ 20093.2% |
| Free Cash Flow | 0▲ 0% | 0▲ 0% | 0▲ 0% | -763.82K▲ 0% | -114.5M▼ 14890.4% |
| FCF Margin % | - | - | - | - | - |
| FCF Growth % | - | - | - | - | -14890.44% |
| FCF per Share | - | - | - | -0.05 | -3.68 |
| FCF Conversion (FCF/Net Income) | - | - | - | 0.01x | 0.85x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 |
BBOT Key Ratios
BridgeBio Oncology Therapeutics Inc. (BBOT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | -78.74% | -44.7% |
| Return on Invested Capital (ROIC) | - | -13.26% | -350050.44% | -64.85% | -96.27% |
| Debt / Equity | - | - | - | - | 0.01x |
| FCF Conversion | - | - | - | 0.01x | 0.85x |
BBOT SEC Filings & Documents
BridgeBio Oncology Therapeutics Inc. (BBOT) SEC filings — annual & quarterly reports (10-K, 10-Q)
BBOT Frequently Asked Questions
BridgeBio Oncology Therapeutics Inc. (BBOT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
BridgeBio Oncology Therapeutics Inc. (BBOT) grew revenue by 0.0% over the past year. Growth has been modest.
BridgeBio Oncology Therapeutics Inc. (BBOT) reported a net loss of $134.0M for fiscal year 2025.
Dividend & Returns
BridgeBio Oncology Therapeutics Inc. (BBOT) has a return on equity (ROE) of -44.7%. Negative ROE indicates the company is unprofitable.
BridgeBio Oncology Therapeutics Inc. (BBOT) had negative free cash flow of $95.5M in fiscal year 2025, likely due to heavy capital investments.
Explore More BBOT
BridgeBio Oncology Therapeutics Inc. (BBOT) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates